Modulation of Alzheimer's pathology by cerebro‐ventricular grafting of hybridoma cells expressing antibodies against Aβ in vivo

Accumulation in brain of the β‐amyloid peptide (Aβ) is considered as crucial pathogenic event causing Alzheimer's disease (AD). Anti‐Aβ immune therapy is a powerful means for Aβ clearance from the brain. We recently showed that intravenous injections of anti‐Aβ antibodies led to reduction, elevation or no change in brain Aβ 42 concentrations of an AD mouse model. We report here, in a second passive immunization protocol, a different bioactivity of same antibodies to alter brain Aβ 42 concentrations. Comparing the bioactivity of anti‐Aβ antibodies in these two passive immunization paradigms underscores the potential of immune therapy for AD treatment and suggests that both the epitope recognized by the antibody and the mode of antibody administration are crucial for its biological activity.